Shares of other companies:
Wall Street Brunch: Here Comes Nvidia
May 19, 2024
A.O. Smith: Great Company, Inferior Investment
May 18, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
AMGN Stock News and Mentions of Amgen Inc. Stocktwits
Updated: May 20, 2024 (09:13)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Amgen Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Amgen Inc. (AMGN).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Amgen stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Amgen Inc. (AMGN)
May 19, 2024 (10:15) / "Motley Fool" (by Adria Cimino)
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Eli Lilly's biggest growth drivers today are its weight loss drugs.
In Article Trend: Neutral
May 18, 2024 (14:19) / "Business Insider" (by Nicolás Jose Rodriguez)
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act ( CSA ) . This shift could revolutionize the cannabis industry. But what exactly is Schedule III? What other substances are produced and studied in this ...
In Article Trend: Somewhat-Bullish
May 18, 2024 (14:19) / "Benzinga" (by Nicolás Jose Rodriguez)
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch - AbbVie ( NYSE:ABBV ) , Amgen ( NASDAQ:AMGN )
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act ( CSA ) . This shift could revolutionize the cannabis industry. But what exactly is Schedule III? What other substances are produced and studied in this ...
In Article Trend: Somewhat-Bullish
May 17, 2024 (19:24) / "Benzinga" (by Zacks)
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly - Altimmune ( NASDAQ:ALT ) , Amgen ( NASDAQ:AMGN )
The obesity market has garnered much interest lately, ever since Novo Nordisk NVO received FDA approval for its obesity drug Wegovy in 2021. It was only after a couple of years that the market gained a second entrant - Eli Lilly's LLY Zepbound, which received FDA approval last year in November.
In Article Trend: Somewhat-Bullish
May 17, 2024 (19:16) / "Benzinga" (by Benzinga Insights)
Amgen Unusual Options Activity - Amgen ( NASDAQ:AMGN )
Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Neutral
May 17, 2024 (15:47) / "Zacks Commentary" (by Zacks Equity Research)
Amgen's ( AMGN ) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
In Article Trend: Neutral
May 17, 2024 (14:04) / "Zacks Commentary" (by Sundeep Ganoria)
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
In Article Trend: Somewhat-Bullish
May 17, 2024 (14:01) / "Benzinga" (by Vandana Singh)
FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients - Amgen ( NASDAQ:AMGN )
Thursday, the FDA approved Amgen Inc's AMGN Imdelltra ( tarlatamab-dlle ) for the treatment of adult patients with extensive-stage small cell lung cancer ( ES-SCLC ) with disease progression on or after platinum-based chemotherapy.
In Article Trend: Neutral
May 17, 2024 (12:24) / "Motley Fool" (by David Jagielski)
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Could Amgen be the next stock to soar due to a GLP-1 drug?
In Article Trend: Somewhat-Bullish
May 16, 2024 (13:44) / "Zacks Commentary" (by Zacks Equity Research)
Roche ( RHHBY ) Posts Encouraging Phase I Obesity Drug Data
Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
In Article Trend: Somewhat-Bullish
May 16, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Amgen Inc. ( AMGN ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
In Article Trend: Somewhat-Bullish
May 16, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks To Watch: Amgen Sees RS Rating Jump To 81
The Relative Strength ( RS ) Rating for Amgen ( AMGN ) climbed into a new percentile Thursday, with an increase from 77 to 81. X This exclusive rating from Investor's Business Daily tracks share price action with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Somewhat-Bullish
May 15, 2024 (20:18) / "Benzinga" (by Piero Cingari)
S&P 500, Nasdaq 100, Dow Jones Shatter Record Highs In Unstoppable Bull Market Rally - Amgen ( NASDAQ:AMGN )
The S&P 500, Nasdaq 100 and Dow Jones Industrial Average indices all shattered fresh all-time highs Wednesday, driven by a benign inflation report that boosted risk sentiment among bullish investors.
In Article Trend: Somewhat-Bullish
May 15, 2024 (19:43) / "Benzinga" (by Zacks)
Should You Hold Viking Therapeutics in Your Portfolio? - Eli Lilly and Co ( NYSE:LLY ) , Amgen ( NASDAQ:AMGN )
Viking Therapeutics VKTX, a clinical-stage company focused on developing novel therapeutics for metabolic and endocrine disorders, has been in the news, owing to updates from its obesity program. The company, with a market cap of about $8 billion, is developing its lead candidate, VK2735, a dual ...
In Article Trend: Somewhat-Bullish
May 15, 2024 (15:36) / "Zacks Commentary" (by Zacks Equity Research)
Should You Hold Viking Therapeutics ( VKTX ) in Your Portfolio?
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
In Article Trend: Somewhat-Bullish
May 15, 2024 (13:53) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly ( LLY ) Settles With Spa Selling Mounjaro, Zepbound Copies
Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.
In Article Trend: Neutral
May 14, 2024 (17:00) / "Zacks Commentary" (by Sanghamitra Saha)
4 Best ETF Areas of Last Week
Wall Street was upbeat last week with the S&P 500 adding 1.9%, the Dow Jones advancing 2.2% and the Nasdaq Composite gained 1.1%.
In Article Trend: Somewhat-Bullish
May 14, 2024 (15:22) / "Forbes" (by Chase Feiger)
Vertex Is Writing A New Playbook For Pharma R&D. And It's Working.
Vertex Pharmaceuticals ( NDAQ: VRTX ) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way, just may have authored a new playbook for life sciences R&D.
In Article Trend: Somewhat-Bullish
May 13, 2024 (12:30) / "Forbes" (by Trefis Team)
Is Eli Lilly Stock A Better Pick Over Amgen?
Given its better prospects, we believe Eli Lilly stock ( NYSE: LLY ) is a better pick than Amgen stock ( NASDAQ : AMGN ) . Both stocks have been in the limelight lately, given their focus on the lucrative weight-loss treatment market. Eli Lilly trades at a higher valuation multiple of 20.4x ...
In Article Trend: Somewhat-Bullish
May 13, 2024 (12:00) / "Zacks Commentary" (by Sanghamitra Saha)
Best Inverse/Leveraged ETFs of Last Week
Wall Street was upbeat last week. Notably, on Friday, the Dow secured its eighth consecutive session of gains.
In Article Trend: Somewhat-Bullish
May 13, 2024 (11:36) / "Zacks Commentary" (by Zacks Investment Research)
The Zacks Analyst Blog Highlights Amgen, Amazon.com, Apple, Boeing and Goldman Sachs
Amgen, Amazon.com, Apple, Boeing and Goldman Sachs are included in this Analyst Blog.
In Article Trend: Somewhat-Bullish
May 12, 2024 (13:15) / "Motley Fool" (by Prosper Junior Bakiny)
Amgen Is Working On a Wegovy Competitor -- What It Means for Investors
The biotech's pipeline extends far beyond this exciting weight-loss product.
In Article Trend: Somewhat-Bullish
May 10, 2024 (15:14) / "Zacks Commentary" (by Sweta Killa)
5 Stocks Driving Dow's Market-Beating Performance
Dow Jones outperforms at the start of May as the market rally broadens and reconstruction of the index finally pays off.
In Article Trend: Somewhat-Bullish
May 9, 2024 (11:30) / "Benzinga" (by Globe Newswire)
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan - Coherus BioSciences ( NASDAQ:CHRS )
- New $38.7 million term loan with a May 2029 maturity - - $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® -
In Article Trend: Neutral
May 9, 2024 (11:27) / "Benzinga" (by Shanthi Rexaline)
S&P 500, Nasdaq To Open Lower Today: What's Dragging Stock Futures? - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
Trading in U.S. index futures suggests stocks may be off to a lackluster start again on Thursday. Much of the negativity in the recent session was triggered by the lack of clarity on the Federal Reserve's rate trajectory. The spotlight is likely to be on another slew of earnings reports and a Fed ...
In Article Trend: Neutral
May 9, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
IBD Rating Upgrades: Amgen Shows Improved Technical Strength
Amgen ( AMGN ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, rising from 62 to 75. X This proprietary rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
In Article Trend: Somewhat-Bullish
May 8, 2024 (16:01) / "Benzinga" (by Benzinga Insights)
Market Whales and Their Recent Bets on AMGN Options - Amgen ( NASDAQ:AMGN )
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen. Looking at options history for Amgen AMGN we detected 17 trades. If we consider the specifics of each trade, it is accurate to state that 23% of the investors opened trades with bullish expectations and 58% with ...
In Article Trend: Neutral
May 8, 2024 (14:51) / "Investors Business Daily" (by VIDYA RAMAKRISHNAN)
Indexes Mixed As Uber Dives On Earnings; Tesla Falls On New Probe As China Ban Hits Intel
Indexes Mixed As Uber Dives On Earnings. Tesla Falls On New Probe As China Ban Hits Intel Investor's Business Daily ...
In Article Trend: Neutral
May 7, 2024 (18:45) / "Benzinga" (by Benzinga Insights)
How Is The Market Feeling About Amgen? - Amgen ( NASDAQ:AMGN )
Amgen's AMGN short percent of float has fallen 3.57% since its last report. The company recently reported that it has 10.11 million shares sold short, which is 1.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.08 days to cover their ...
In Article Trend: Somewhat-Bullish
May 7, 2024 (15:25) / "StockMarket.com" (by Josh Dylan)
Best Dow Jones Stocks To Buy Right Now? 2 For Your Watch List
The stock market is where investors buy and sell shares of public companies. Among the various indexes, the Dow Jones Industrial Average ( DJIA ) is one of the most recognized.
In Article Trend: Somewhat-Bullish
May 7, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
In Article Trend: Somewhat-Bullish
May 7, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Amgen Inc. ( AMGN ) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
May 6, 2024 (14:41) / "Investors Business Daily" (by MICHAEL LARKIN)
Dow Jones Up As Apple Falls; Warren Buffett Stock Steady Despite This Loss
Dow Jones Up As Apple Falls. Warren Buffett Stock Steady Despite This Loss Investor's Business Daily ...
In Article Trend: Neutral
May 6, 2024 (14:17) / "Benzinga" (by Benzinga Insights)
Check Out What Whales Are Doing With AMGN - Amgen ( NASDAQ:AMGN )
Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Neutral
May 6, 2024 (13:35) / "Zacks Commentary" (by Zacks Equity Research)
Company News for May 6, 2024
Companies in The News Are: HSY, AMGN, MELI, ...
In Article Trend: Somewhat-Bullish
May 5, 2024 (20:01) / "Business Insider" (by Shanthi Rexaline)
Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update
Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity ... - Markets Insider ...
In Article Trend: Somewhat-Bullish
May 5, 2024 (19:16) / "Benzinga" (by Shanthi Rexaline)
Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update - ARK Genomic Revolution ETF ( BATS:ARKG ) , Amgen ( NASDAQ:AMGN )
Cathie Wood-run Ark Invest on Friday picked up shares of a biopharma company after it revealed significant progress with it weight-loss drug candidate. What Happened: Ark, through its ARK Genomic Revolution ETF ARKG, bought 11,360 shares of Amgen, Inc. AMGN, which rallied nearly 12% on Friday.
In Article Trend: Somewhat-Bullish
May 5, 2024 (15:16) / "Stocknews.com" (by Defense World Staff)
Amgen ( NASDAQ:AMGN ) Upgraded by StockNews.com to Buy
Amgen ( NASDAQ:AMGN - Get Free Report ) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on Friday. Other equities research analysts also recently issued reports about the stock.
In Article Trend: Somewhat-Bullish
May 3, 2024 (22:19) / "Motley Fool" (by JesterAI)
Amgen Delivers a Q1 Earnings Beat
While revenue met Wall Street's expectations, earnings surpassed them.
In Article Trend: Somewhat-Bullish
May 3, 2024 (22:15) / "Motley Fool" (by Eric Volkman)
Why Amgen Stock Zoomed Nearly 12% Higher Today
The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.
In Article Trend: Somewhat-Bullish
May 3, 2024 (20:10) / "Barrons" (by Barron's Automation)
U.S. Markets Moved Upward Friday; Amgen Climbed Highest
U.S. Markets Moved Upward Friday. Amgen Climbed Highest ...
In Article Trend: Somewhat-Bullish
May 3, 2024 (20:08) / "Kiplinger" (by Karee Venema)
Stock Market Today: Stocks Soar on Apple Buyback News, Jobs Data
Stocks jumped out of the gate Friday and never looked back. Sentiment got a major lift thanks to a positive reaction to Apple's ( AAPL ) quarterly earnings report and a bad-news-is-good-news jobs report.
In Article Trend: Somewhat-Bullish
May 3, 2024 (17:51) / "Benzinga" (by Piero Cingari)
Stocks Rally As Jobs Report Rekindles Rate Cut Hopes, Apple Rockets, Bitcoin Soars Above $61,000: What's Driving Markets Friday? - Amgen ( NASDAQ:AMGN )
A weaker-than-expected jobs report sparked a widespread market rally in the last session of the week, as traders increased expectations on potential interest rate cuts later this year.
In Article Trend: Somewhat-Bullish
May 3, 2024 (17:18) / "Investors Business Daily" (by IBD STAFF)
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
The stock market rallied for the week, with Friday's weaker-than-expected jobs report bolstering a relatively dovish Federal Reserve and Fed chief Jerome Powell on Wednesday. The S&P 500 and Nasdaq tested key levels. Apple ( AAPL ) soared on a record buyback and earnings that were better than ...
In Article Trend: Neutral
May 3, 2024 (15:48) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Q1 Earnings Top, Stock Up on Obesity Drug Update
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
In Article Trend: Somewhat-Bullish
May 3, 2024 (15:33) / "Business Insider" (by Vandana Singh)
Amgen Outlook Is Bright, Analyst Predict Obesity-Focused Drug Potential Will Drive Shareholder Value
Amgen Inc ( NASDAQ:AMGN ) reported first-quarter ( Q1 ) earnings Thursday, touting adjusted EPS of $3.96, which beat the analyst consensus estimate of $3.87.
In Article Trend: Somewhat-Bullish
May 3, 2024 (15:24) / "Benzinga" (by Vandana Singh)
Amgen Outlook Is Bright, Analyst Predict Obesity-Focused Drug Potential Will Drive Shareholder Value - Amgen ( NASDAQ:AMGN )
Amgen Inc AMGN reported first-quarter ( Q1 ) earnings Thursday, touting adjusted EPS of $3.96, which beat the analyst consensus estimate of $3.87. Here are highlights from the release and subsequent analyst call: Sales increased 22% Y/Y to $7.45 billion, which beat the analyst consensus ...
In Article Trend: Somewhat-Bullish
May 3, 2024 (14:41) / "Investors Business Daily" (by KEN SHREVE)
Dow Jones Soars 400 Points As Amgen, Apple Surge; Nvidia Jumps Again, Tempts New Buyers
Stock Market Today: Dow Jones Surges, Led By Amgen, Apple. Nvidia Jumps Above Key Level Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
May 3, 2024 (14:15) / "Benzinga" (by Avi Kapoor)
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday - Amgen ( NASDAQ:AMGN )
U.S. stocks were higher, with the Dow Jones index gaining over 400 points on Friday. Shares of Amgen Inc. AMGN rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results. Also, the company announced a $50 million milestone payment from ...
In Article Trend: Bullish
May 3, 2024 (11:03) / "Benzinga" (by Shanthi Rexaline)
Nasdaq, S&P 500 Futures Signal Higher Open On Apple's Boost: Will Non-Farm Payrolls Data Play Spoilsport? - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
Stocks look set to carry forward the upward momentum on Friday amid some earnings cheer, although a tinge of nervousness is evident ahead of the all-important non-farm payrolls report.
In Article Trend: Neutral
May 3, 2024 (07:45) / "Benzinga" (by Shanthi Rexaline)
Amgen Stock Adds Good Weight After CEO's Update On Experimental Drug Rivaling Ozempic, Nixing Oral Weight-Loss Candidate - Amgen ( NASDAQ:AMGN )
Amgen, Inc. AMGN shares rallied over 14% in Thursday's after-hours trading after the biopharma reported a double beat and offered an update on its obesity drug pipeline. What Happened: Amgen said on the call that it was pulling the plug on AMG 786, an oral Phase 1 candidate for obesity. "We will ...
In Article Trend: Somewhat-Bullish
May 2, 2024 (21:44) / "Benzinga" (by Erica Kollmann)
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment - Amgen ( NASDAQ:AMGN )
Amgen Inc. AMGN reported first-quarter financial results after the closing bell Thursday. Here's a look at the highlights. The Details: Amgen reported quarterly earnings of $3.96 per share, which beat the analyst consensus estimate of $3.87 by 2.33%.
In Article Trend: Bullish
May 2, 2024 (20:24) / "Investors Business Daily" (by Investor's Business Daily)
Amgen Falls On Quarterly Beat As Obesity Space Heats Up
Amgen Stock Dips Despite Quarterly Beat As Investors Watch The Obesity Space Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
May 2, 2024 (17:31) / "Benzinga" (by Benzinga Insights)
Amgen's Options: A Look at What the Big Money is Thinking - Amgen ( NASDAQ:AMGN )
Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Somewhat-Bullish
May 2, 2024 (10:52) / "Benzinga" (by Shanthi Rexaline)
Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: What's Going On With Stock Market? - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
U.S. stocks look to push ahead on a positive path, now that the Federal Reserve's rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday.
In Article Trend: Neutral
May 1, 2024 (16:05) / "Benzinga" (by Erica Kollmann)
What's Going On With CytomX Stock? - CytomX Therapeutics ( NASDAQ:CTMX )
CytomX Therapeutics, Inc. CTMX shares are racing higher Wednesday. The company said it will report first-quarter results and provide an initial CX-904 Phase 1a dose escalation update on May 8 after the close of markets. CytomX and Amgen, Inc.
In Article Trend: Bullish
April 30, 2024 (15:54) / "Benzinga" (by Vandana Singh)
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab - Amgen ( NASDAQ:AMGN )
Generic and biosimilar manufacturer Sandoz AG SDZNY SDZXF reached an agreement on Tuesday with Amgen Inc AMGN to resolve all patent litigation related to its U.S. denosumab biosimilars.
In Article Trend: Neutral
April 30, 2024 (15:20) / "Zacks Commentary" (by Zacks Equity Research)
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
In Article Trend: Somewhat-Bullish
April 30, 2024 (05:00) / "Benzinga" (by Globe Newswire)
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars - Sandoz Group ( OTC:SDZNY )
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Agreement clears path for launch of Jubbonti® and Wyost® on May 31, 2025 or earlier under certain circumstances Jubbonti® and Wyost® are first and only FDA-approved biosimilars to and interchangeable with Prolia*® and Xgeva*®
In Article Trend: Neutral
April 29, 2024 (16:35) / "Zacks Commentary" (by Zacks Equity Research)
What's in the Cards for Amgen ( AMGN ) This Earnings Season?
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
In Article Trend: Somewhat-Bullish
April 29, 2024 (14:47) / "Investors Business Daily" (by Investor's Business Daily)
Dow Jones Up As Warren Buffett Stocks Eye Entries; Elon Musk Makes This AI Boast
Dow Jones Up As Warren Buffett Stocks Eye Entries. Elon Musk Makes This AI Boast Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 29, 2024 (13:16) / "Zacks Commentary" (by Zacks Equity Research)
Insights Into Amgen ( AMGN ) Q1: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
In Article Trend: Neutral
April 29, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
April 29, 2024 (05:51) / "Benzinga" (by Shanthi Rexaline)
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
Corporate earnings came to the market's rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it remains to be seen whether the tech earnings deluge can keep the rally's momentum going.
In Article Trend: Somewhat-Bullish
April 26, 2024 (22:17) / "Investors Business Daily" (by ALAN R. ELLIOTT)
Apple, Amazon, Big Pharma And The Fed: Investing Action Plan
A Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 25, 2024 (20:45) / "PR Newswire" (by Inc.)
Mahesh Krishnan Elected to Halozyme's Board of Directors
SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. ( NASDAQ: HALO ) ( "Halozyme" ) today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
In Article Trend: Somewhat-Bullish
April 25, 2024 (17:47) / "Zacks Commentary" (by Zacks Equity Research)
AstraZeneca ( AZN ) Q1 Earnings & Sales Beat Estimates, Stock Up
AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
In Article Trend: Neutral
April 25, 2024 (14:02) / "Zacks Commentary" (by Zacks Equity Research)
Analysts Estimate Amgen ( AMGN ) to Report a Decline in Earnings: What to Look Out for
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 24, 2024 (18:29) / "Benzinga" (by Vandana Singh)
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? - Cullinan Therapeutics ( NASDAQ:CGEM )
A recent academic case study, published on April 22, examined using Amgen Inc's AMGN Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The findings have implications for Cullinan Therapeutics Inc's CGEM CLN-978, a similar CD19xCD3 bispecific T-cell ...
In Article Trend: Somewhat-Bullish
April 24, 2024 (16:05) / "Zacks Commentary" (by Sweta Killa)
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
In Article Trend: Neutral
April 24, 2024 (14:02) / "GlobeNewswire" (by Inc.)
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology ( ASCO ) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( Coherus, Nasdaq: CHRS ) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 ...
In Article Trend: Neutral
April 23, 2024 (13:15) / "Motley Fool" (by George Budwell)
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment?
In Article Trend: Somewhat-Bullish
April 23, 2024 (12:15) / "Motley Fool" (by George Budwell)
1 No-Brainer Vanguard Fund to Buy Right Now
This Vanguard growth fund is home to some of the world's most innovative companies.
In Article Trend: Somewhat-Bullish
April 22, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Amgen ( AMGN ) Outpaced the Stock Market Today
In the most recent trading session, Amgen (AMGN) closed at $271.48, indicating a +0.95% shift from the previous trading day.
In Article Trend: Neutral
April 22, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Neutral
April 19, 2024 (13:45) / "Benzinga" (by Benzinga Insights)
How Is The Market Feeling About Amgen? - Amgen ( NASDAQ:AMGN )
Amgen's AMGN short percent of float has fallen 5.77% since its last report. The company recently reported that it has 10.47 million shares sold short, which is 1.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.83 days to cover their ...
In Article Trend: Somewhat-Bullish
April 18, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.
In Article Trend: Neutral
April 18, 2024 (12:51) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly's ( LLY ) Tirzepatide Meets Goals in Sleep Apnea Studies
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.
In Article Trend: Neutral
April 17, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Suffers a Larger Drop Than the General Market: Key Insights
Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.
In Article Trend: Neutral
April 17, 2024 (18:39) / "Benzinga" (by Vandana Singh)
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick - AstraZeneca ( NASDAQ:AZN ) , Amgen ( NASDAQ:AMGN )
Tuesday, Amgen Inc AMGN provided an update regarding the results of the Phase 2a COURSE trial for Tezspire ( tezepelumab-ekko ) in chronic obstructive pulmonary disease ( COPD ) . Tezspire is a registered trademark of Amgen and AstraZeneca Plc AZN.
In Article Trend: Somewhat-Bullish
April 17, 2024 (12:21) / "Benzinga" (by Avi Kapoor)
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Visa ( NYSE:V )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut the price target for Unity Biotechnology, Inc. UBX from $10 to $8.
In Article Trend: Neutral
April 17, 2024 (11:30) / "Motley Fool" (by George Budwell)
Can This High-Yield Dividend Stock Keep Beating the S&P 500?
Amgen's shares have come under pressure this year, making it a compelling bargain buy.
In Article Trend: Somewhat-Bullish
April 17, 2024 (08:30) / "Motley Fool" (by James Brumley)
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.
In Article Trend: Somewhat-Bullish
April 15, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
April 15, 2024 (13:07) / "Zacks Commentary" (by Zacks Equity Research)
Amgen Inc. ( AMGN ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
April 15, 2024 (12:29) / "Benzinga" (by Avi Kapoor)
Amgen, Shell And More On CNBC's 'Final Trades' - Shell ( NYSE:SHEL ) , Amgen ( NASDAQ:AMGN )
On CNBC's "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust said Shell plc SHEL has 12% free On April 5, Shell updated its first quarter FY24 operational outlook, reflecting lower results from its liquefied natural gas ( LNG ) trading business.
In Article Trend: Somewhat-Bullish
April 12, 2024 (16:31) / "Benzinga" (by Benzinga Insights)
Looking At Amgen's Recent Unusual Options Activity - Amgen ( NASDAQ:AMGN )
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 13 unusual trades. Delving into the details, we found 46% of traders were bullish, while 53% showed bearish tendencies.
In Article Trend: Neutral
April 11, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Laps the Stock Market: Here's Why
In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
April 11, 2024 (12:00) / "Motley Fool" (by David Jagielski)
Is Amgen Stock a Buy?
Amgen's stock isn't expensive, but the business does face some challenges, which could have investors thinking twice.
In Article Trend: Neutral
April 9, 2024 (11:02) / "Zacks Commentary" (by Zacks Equity Research)
Biophytis ( BPTS ) to Begin Phase II Obesity Study, Stock Up
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.
In Article Trend: Somewhat-Bullish
April 9, 2024 (11:00) / "Business Insider" (by Chris MacDonald)
3 High-Growth Biotech Stocks Investors Shouldn't Sleep On in April
It's been a volatile start to the second quarter for many sectors. However, investors continue to seek out undervalued biotech stocks for robust returns over the long term. Plenty of options exist in various niches within the biotech sector.
In Article Trend: Somewhat-Bullish
April 8, 2024 (22:42) / "GlobeNewswire" (by Opthea Limited)
Opthea Appoints John Han, PharmD, as VP Medical Affairs
Brings extensive experience in retinal and ophthalmology diseases Brings extensive experience in retinal and ophthalmology diseases ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
April 8, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting - Coherus BioSciences ( NASDAQ:CHRS )
- In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion - - Mechanism may enhance antitumor responses with immunotherapy - - First novel immuno-oncology ...
In Article Trend: Neutral
April 6, 2024 (12:45) / "Motley Fool" (by Prosper Junior Bakiny)
2 Biotech Stocks to Buy Hand Over Fist in April
These drugmakers have made important moves over the past year.
In Article Trend: Somewhat-Bullish
April 5, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Ascends But Remains Behind Market: Some Facts to Note
Amgen (AMGN) concluded the recent trading session at $269.95, signifying a +0.69% move from its prior day's close.
In Article Trend: Somewhat-Bullish
April 5, 2024 (16:35) / "Investors Business Daily" (by ALLISON GATLIN)
Why A Pullback Is Bullish For IBD Stock Of The Day Novo Nordisk
Novo Nordisk ( NVO ) is Friday's IBD Stock Of The Day. After hitting a record high in March, shares have pulled back amid new developments in the weight-loss drugs frenzy. Last month, Novo said its next-generation weight-loss pill, amycretin, outperformed blockbuster Wegovy in an early-stage ...
In Article Trend: Somewhat-Bullish
April 5, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is iShares Biotechnology ETF ( IBB ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 5, 2024 (08:05) / "Motley Fool" (by James Brumley)
3 Stocks to Consider Adding to Your Retirement Portfolio in April
Use the recent short-term weakness from these powerhouse companies' stocks to your advantage.
In Article Trend: Somewhat-Bullish
April 3, 2024 (15:14) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Amgen ( AMGN ) Stock is Outperforming the Industry
Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to make up for lower revenues from oncology biosimilars and ...
In Article Trend: Somewhat-Bullish
April 2, 2024 (18:15) / "Benzinga" (by Benzinga Insights)
Amgen Unusual Options Activity For April 02 - Amgen ( NASDAQ:AMGN )
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 11 unusual trades. Delving into the details, we found 18% of traders were bullish, while 81% showed bearish tendencies.
In Article Trend: Neutral
April 2, 2024 (14:52) / "Investors Business Daily" (by Investor's Business Daily)
Dow Jones Dives As Calvin Klein Parent Craters; Cathie Wood Loads Up On This Stock Amid 45% Downtrend
Dow Jones Dives As Calvin Klein Parent Craters. Cathie Wood Loads Up On This Stock Amid 45% Downtrend Investor's Business Daily ...
In Article Trend: Neutral
April 1, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Amgen (AMGN) closed the most recent trading day at $283.04, moving -0.45% from the previous trading session.
In Article Trend: Somewhat-Bullish
April 1, 2024 (16:10) / "Zacks Commentary" (by Zacks Equity Research)
Why Amgen ( AMGN ) is Poised to Beat Earnings Estimates Again
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In Article Trend: Somewhat-Bullish
April 1, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
April 1, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Invesco Pharmaceuticals ETF ( PJP ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (08:24) / "PR Newswire"
Enzyme-linked immunosorbent assay (Elisa) testing market size to Increase by USD 564.97 million between 2022 ... - PR Newswire
Enzyme-linked immunosorbent assay ( Elisa ) testing market size to Increase by USD 564.97 million between 2022 ... PR ...
In Article Trend: Somewhat-Bullish
March 29, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Amgen Inc. ( AMGN ) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
March 29, 2024 (08:50) / "Stocknews.com" (by Defense World Staff)
Amgen ( NASDAQ:AMGN ) Downgraded by StockNews.com to Hold
StockNews.com lowered shares of Amgen ( NASDAQ:AMGN - Free Report ) from a buy rating to a hold rating in a research report report published on Thursday. Several other equities analysts have also weighed in on the stock.
In Article Trend: Somewhat-Bullish
March 28, 2024 (18:28) / "Benzinga" (by Vandana Singh)
Amgen's Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst Says - Amgen ( NASDAQ:AMGN )
Raymond James has resumed coverage of Amgen Inc AMGN, noting a diversified portfolio where Amgen has a strong presence that can help drive solid, sustainable long-term growth.
In Article Trend: Somewhat-Bullish
March 28, 2024 (16:03) / "Benzinga" (by Benzinga Insights)
Amgen Options Trading: A Deep Dive into Market Sentiment - Amgen ( NASDAQ:AMGN )
Deep-pocketed investors have adopted a bullish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
In Article Trend: Bullish
March 28, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the iShares Biotechnology ETF ( IBB ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (12:10) / "Zacks Commentary" (by Zacks Equity Research)
Precision BioSciences ( DTIL ) Reports Q4 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -211.67% and 75.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 26, 2024 (14:21) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Awaits Consumer Confidence Data
U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility. The AI-driven rally of the last 15 months is showing no sign of losing pace.
In Article Trend: Neutral
March 26, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should Schwab U.S. Dividend Equity ETF ( SCHD ) Be on Your Investing Radar?
Style Box ETF report for ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (06:33) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Set to Post Fifth Winning Month Amid Volatility
Wall Street is likely to record the fifth consecutive winning month despite volatility.
In Article Trend: Neutral
March 25, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Amgen (AMGN) closed at $280.82, indicating a +1.68% shift from the previous trading day.
In Article Trend: Neutral
March 25, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
March 22, 2024 (16:18) / "PR Newswire"
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website